In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $50.71, marking a -2.59% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.04%.

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

We'll know more about the company's medium-term prospects by the end of the year.

Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there ...

The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial ...

The U.S. FDA has begun piloting real-time clinical trial tracking in two cancer studies to speed up safety and efficacy monitoring. The move comes as CRISPR Therapeutics attracts investor attention ...

For most of their lives, plants get their energy from photosynthesis. But during the seed to seedling stage, when they can't ...

The cultivar is giving the industry renewed confidence in the future, said Florida Citrus Mutual Board President Kevin ...